Showing results (291-300 of 311) with videos related to

Sort By:
Pageof 32
Journal of Materials Chemistry. B|June 16, 2025
Towards the development of supramolecular self-associating amphiphiles as antibiofilm agents against Pseudomonas aeruginosa and Candida albicans biofilmsKira L F Hilton, Hendrik J F Steyn, Kusasalethu S Luthuli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkersTimothy A Yap, Li Yan, Amita Patnaik, et al.
World Neurosurgery|January 10, 2016
A Modern Radiotherapy Series of Survival in Hispanic Patients with GlioblastomaCheng-Chia Wu, Tony J C Wang, Ashish Jani, et al.
Practical Radiation Oncology|March 9, 2016
Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastomaTony J C Wang, Cheng-Chia Wu, Ashish Jani, et al.
Psychiatric Services (Washington, D.C.)|January 25, 2023
Youth Mental Health Screening and Linkage to CareNicole R Karcher, Ramona Hicks, Jason Schiffman, et al.
Nature Communications|May 12, 2026
Social implications of the 30×30 global conservation targetJavier Fajardo, Heather C Bingham, Dan Brockington, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Chemical Science|March 12, 2026
Amino acid appended supramolecular self-associating amphiphiles demonstrate dual activity against both MRSA and ovarian cancerPrecious I A Popoola, Thomas L Allam, Rebecca J Lilley, et al.
JCI Insight|October 10, 2022
CD11c+ myeloid cell exosomes reduce intestinal inflammation during colitisKaylyn M Bauer, Morgan C Nelson, William W Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Pageof 32